Fig. 2

Relationship between RBM47 and clinical pathological features. (A–D) Relationship between RBM47 expression and WHO grade, IDH status, 1p/19q co-deletion, and MGMT status in the CGGA dataset. (E–H) TCGA dataset yielded similar results. Sample sizes in the CGGA dataset: WHO II n = 97; WHO III n = 73; WHO IV n = 134; IDH mutant type n = 163; IDH wild type n = 141; 1p/19q co-deletion n = 62; 1p/19q non-co-deletion n = 242; DNA methylated n = 147; DNA un-methylated n = 139. Sample sizes in TCGA dataset: WHO II n = 211; WHO III n = 238; WHO IV n = 143; IDH mutant type n = 372; IDH wild type n = 220; 1p/19q co-deletion n = 149; 1p/19q non-co-deletion n = 443; DNA methylated n = 419; DNA un-methylated n = 143. The differences between groups were analyzed using the Wilcoxon rank-sum test. P < 0.05 was considered significantly different.